Clinical Trials
180 trialsAcquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Massachusetts General Hospital
MDS
National Heart, Lung, and Blood Institute (NHLBI)
REBOUND
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Novartis
MPN-COVID
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
KID-Tryp
Assistance Publique - Hôpitaux de Paris
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
Novartis
Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells
Asan Medical Center
A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
Novartis
BabyDetect
Centre Hospitalier Universitaire de Liege
MASCOT-R
Royal Free Hospital NHS Foundation Trust
MonSThr
University Hospital, Bordeaux
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
University of Milano Bicocca
TIKlet
University of Pisa
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
Mayo Clinic
CAP
Eulji University Hospital
CML0912
Gruppo Italiano Malattie EMatologiche dell'Adulto
RevlimidPMS
Celgene
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Ann & Robert H Lurie Children's Hospital of Chicago
SYTHROM
Nantes University Hospital
GITMO AML/MDS-Relapse Registry Study
Gruppo Italiano Trapianto di Midollo Osseo
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
UNC Lineberger Comprehensive Cancer Center
ROOT
Taproot Health
ABL-2022-03
Novartis
PANAM
University Hospital, Brest
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Swedish Orphan Biovitrum
PV-ARC
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PAVE
Novartis
BLF
Pfizer
Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms
Federico II University
Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide
Qianfoshan Hospital
SARS-CoV-2 Donor-Recipient Immunity Transfer
City of Hope Medical Center
Special Drug Use-results Surveillance of Scemblix Tablets
Novartis
Registry on Hypomethylating Agents in Myeloid Neoplasms
Arbeitsgemeinschaft medikamentoese Tumortherapie
Effect of 2nd Gen TKI in CML
European Society for Blood and Marrow Transplantation
KIWIS
University Hospital, Caen
EMATO0113
Gruppo Italiano Malattie EMatologiche dell'Adulto
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
MOSAICC
Queen's University, Belfast
METER
AbbVie
PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES
AUSL Romagna Rimini
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
Novartis
Early Detection of Epstein-Barr Virus Related Disease.
University of Aarhus
Effect of Pharmacogenetics on Imatinib Plasma Level and Response
Assiut University
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Pfizer
Chemobrain
University of Nebraska
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
Incyte Corporation
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis
Polish Adult Leukemia Group
NOFRETETE
Novartis